VCM
ORKA

Versant Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Versant Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.33K Hold
98
– – ﹤0.01% 2253
2026
Q1 		$4.81K Buy
+98
New +$3.41K ﹤0.01% 2391

Other funds holding ORKA

SAM
Synergy Asset Management Vancouver, Washington $1.06B AUM 36.26% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
SAM
Secure Asset Management Troy, Michigan $714M AUM 27.91% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
EWM
Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
BIG
Brookwood Investment Group Phoenix, Arizona $888M AUM 32.21% 1-Year Est. Return
CUAMC
China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return
AA
AlphaCentric Advisors San Juan, Puerto Rico $118M AUM

Versant Capital Management's ORKA Position: Q2 2026 in Review

Versant Capital Management held its Oruka Therapeutics (ORKA) position steady in Q2 2026 at 98 shares worth $9.33K. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

Versant Capital Management first reported a position in ORKA in Q1 2026 and has held it in 2 quarters since. 25 funds tracked by Wall St. Rank hold ORKA as of Q2 2026.

  • Versant Capital Management held 98 shares of Oruka Therapeutics worth $9.33K as of Q2 2026.
  • Versant Capital Management left its Oruka Therapeutics share count unchanged in Q2 2026.
  • Oruka Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2253 holding.
  • Versant Capital Management first reported a position in Oruka Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 25 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.